Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Editas Medicine ( (EDIT) ) just unveiled an announcement.
Editas Medicine has announced a strategic shift towards focusing solely on in vivo gene editing, discontinuing its ex vivo renizgamglogene autogedtemcel program for sickle cell disease and beta thalassemia. This pivot involves reducing its workforce by 65% and is expected to extend the company’s cash runway into 2027, positioning it to achieve human proof of concept in two years and expand its therapeutic possibilities in gene editing.
More about Editas Medicine
Editas Medicine is a leading gene editing company focused on developing transformative, durable, precision in vivo gene editing medicines using CRISPR/Cas12a and CRISPR/Cas9 systems. The company aims to address serious diseases globally and holds exclusive licenses for certain CRISPR patent estates from Broad Institute and Harvard University.
YTD Price Performance: -80.36%
Average Trading Volume: 2,269,149
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $164.3M
For an in-depth examination of EDIT stock, go to TipRanks’ Stock Analysis page.
